Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sci-110 save search
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Published: 2024-01-29 (Crawled : 12:30) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: -1.96%
H: 6.87%
C: -13.75%
sci-210 children trial
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
Published: 2023-11-15 (Crawled : 13:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 65.37%
H: 3.33%
C: -10.4%
positive treatment alzheimer's impact results show sci-110 cannamide dronabinol
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
Published: 2023-09-29 (Crawled : 12:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: -5.31%
H: 6.71%
C: -1.96%
sci-210 trial initiated sci-110
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 10.97%
H: 7.43%
C: -12.87%
sci-110 trial
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Published: 2023-07-14 (Crawled : 12:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 2.68%
H: 0.02%
C: -4.24%
sci-210 children trial sci-110
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
Published: 2023-06-30 (Crawled : 13:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 1.71%
H: 0.0%
C: -8.52%
sci-110 approval germany treat trial
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
Published: 2023-06-05 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.15%
H: 1.08%
C: 0.28%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.29%
H: 0.88%
C: 0.02%
ibi110 asco meeting
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
Published: 2023-04-04 (Crawled : 12:20) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 3.15%
H: 1.59%
C: 0.63%
sci-110 approval trial
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
Published: 2023-03-09 (Crawled : 13:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 1.39%
H: 0.14%
C: -2.05%
sci-110 trial approval
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
Published: 2023-03-06 (Crawled : 13:00) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: 3.85%
H: 1.6%
C: -4.88%
sci-110 drug candidate trial
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Published: 2022-12-09 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.33%
H: 0.27%
C: -3.22%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.05%
H: 0.4%
C: -2.15%
ibi110 medical update
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ibi110 antibody
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.88%
H: 0.51%
C: -0.15%
ibi110 trials antibody
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
solid tumors results trial trial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.